In a candid conversation, tennis legend Serena Williams sheds light on her experience with GLP-1 medication, revealing her journey towards body positivity and health. As a mother of two and a 23-time ...

The drug, which is estimated to be taken by up to 750,000 people, is one of the country's most popular weight loss and ...

Serena Williams' revelation on Thursday that she'd lost 31 pounds came with another confession. Fans were angered with ...

The people of Northern Gaza are starving. That’s according to an official declaration by a United Nations-backed group of ...

In the past couple years, demand has gone wild for drugs like Ozempic – and its cousins, Zepbound, Wegovy, and Mounjaro. For ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Serena Williams has revealed she lost 31 pounds on the GLP-1 Zepbound: "I just couldn't get my weight to where I needed to be at a healthy place." ...

People with type 2 diabetes treated with GLP-1 receptor agonists may face a slightly higher risk for eye complications ...

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

A new imaging approach reveals how dual agonist drugs like tirzepatide act on the pancreas and brain to regulate blood sugar and appetite.

Tennis champion Serena Williams has divided the internet after revealing she’s been using a GLP-1 weight loss drug. The ...